Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 1/20 | 0.40 |
| ▸ | PPARA | Q07869 | 1/20 | 0.40 |
| ▸ | USP14 | P54578 | 1/20 | 0.35 |
| ▸ | BACE1 | P56817 | 1/20 | 0.35 |
| ▸ | LTA4H | P09960 | 1/20 | 0.34 |
| ▸ | IDO1 | P14902 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
| ▸ | ESR1 | P03372 | 2/20 | 0.32 |
| ▸ | AGXT | P21549 | 2/20 | 0.32 |
| ▸ | NOS3 | P29474 | 1/20 | 0.32 |
| ▸ | NOS1 | P29475 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | DUT | P33316 | 2/20 | 0.32 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12002629 | 0.87 | IDO1 (0.40) | PPARGPPARAIDO1ALDH1A1HPGD | |
| SCHEMBL906834 | 0.86 | IDO1 (0.48) | BACE1IDO1TSHRHPGDESR1 | |
| SCHEMBL20570163 | 0.86 | ALDH1A1 (0.34) | USP14ALDH1A1POLBMEN1KMT2A | |
| SCHEMBL31138172 | 0.85 | BACE1 (0.36) | USP14BACE1IDO1ESR1AGXT | |
| SCHEMBL2876790 | 0.85 | CA2 (0.45) | PPARABACE1LTA4HTSHRALDH1A1 | |
| SCHEMBL1206636 | 0.84 | CA12 (0.38) | PPARGPPARAUSP14 | |
| SCHEMBL1628837 | 0.84 | DUT (0.43) | PPARGPPARALTA4HKMT2ADUT | |
| SCHEMBL7174917 | 0.83 | CA2 (0.37) | PPARGPPARAUSP14BACE1POLB | |
| SCHEMBL12855670 | 0.82 | AGXT (0.52) | USP14IDO1TSHRSMN1; SMN2AGXT | |
| SCHEMBL15489965 | 0.82 | TDP1 (0.37) | BACE1ALDH1A1AGXTKMT2ADUT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4714949-A1 | NOVEL COMPOUNDS CAPABLE OF INDUCING OSTEOGENIC DIFFERENTIATION | AJOU UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) | 2026-03-25 | — | — | EP | disclosed |
| US-20250325678-A1 | CYCLIC-AMP RESPONSE ELEMENT BINDING PROTEIN (CBP) AND/OR ADENOVIRAL E1A BINDING PROTEIN OF 300 KDA (P300) DEGRADATION COMPOUNDS AND METHODS OF USE | CULLGEN SHANGHAI INC (CN) | 2025-10-23 | — | — | US | disclosed |
| EP-4581025-A1 | PYRIDAZINON DERIVATIVES AS KAT2 DEGRADERS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | Auron Therapeutics, Inc. (US) | 2025-07-09 | — | — | EP | disclosed |
| WO-2024237721-A1 | NOVEL COMPOUNDS CAPABLE OF INDUCING OSTEOGENIC DIFFERENTIATION | 아주대학교산학협력단 | 2024-11-21 | — | — | WO | disclosed |
| WO-2024050078-A1 | PYRIDAZINON DERIVATIVES AS KAT2 DEGRADERS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | AURON THERAPEUTICS, INC. (US) | 2024-03-07 | — | — | WO | disclosed |
| US-20240066133-A1 | THERAPEUTIC AGENTS AND CONJUGATES THEREOF | AJ SCIENCES (YIXING) CO., LTD (CN) | 2024-02-29 | — | — | US | disclosed |
| US-20240066133-A1 | THERAPEUTIC AGENTS AND CONJUGATES THEREOF | AJ SCIENCES (YIXING) CO., LTD (CN) | 2024-02-29 | — | — | US | disclosed |
| US-20240066133-A1 | THERAPEUTIC AGENTS AND CONJUGATES THEREOF | AJ SCIENCES (YIXING) CO., LTD (CN) | 2024-02-29 | — | — | US | disclosed |
| US-20240050428-A1 | COMPOUNDS AND METHODS OF TREATING CANCERS | CULLGEN (SHANGHAI), INC. (CN) | 2024-02-15 | — | — | US | disclosed |
| CN-116583509-A | Compounds and methods for treating cancer | 上海睿跃生物科技有限公司 | 2023-08-11 | — | — | CN | disclosed |
| US-5653914-A | Electroluminescent device comprising a chromophoric polymeric composition | CAMBRIDGE DISPLAY TECHNOLOGY LIMITED (GB) | 1997-08-05 | — | — | US | disclosed |
| EP-0784612-A1 | UREA DERIVATIVES AND THEIR USE AS ACAT-INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1997-07-23 | — | — | EP | disclosed |
| WO-1996010559-A1 | UREA DERIVATIVES AND THEIR USE AS ACAT-INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1996-04-11 | — | — | WO | disclosed |
| EP-0333758-B1 | CONTROL OF MOLECULAR WEIGHT AND END GROUP FUNCTIONALITY OF POLYMERS | COMMW SCIENT IND RES ORG (AU) | 1995-11-02 | — | — | EP | disclosed |
| US-5385996-A | Control of molecular weight and end-group functionality of polymers | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 1995-01-31 | — | — | US | disclosed |
| WO-1994015441-A1 | ELECTROLUMINESCENT DEVICE COMPRISING A CHROMOPHORIC POLYMERIC COMPOSITION | CAMBRIDGE DISPLAY TECHNOLOGY LIMITED (GB) | 1994-07-07 | — | — | WO | disclosed |
| US-5238832-A | Lipoxygenase inhibitors | BOARD OF GOVERNORS OF WAYNE STATE UNIVERSITY (US) | 1993-08-24 | — | — | US | disclosed |
| EP-0333758-A4 | CONTROL OF MOLECULAR WEIGHT AND END GROUP FUNCTIONALITY OF POLYMERS. | COMMW SCIENT IND RES ORG (AU) | 1990-05-14 | — | — | EP | disclosed |
| EP-0333758-A1 | CONTROL OF MOLECULAR WEIGHT AND END GROUP FUNCTIONALITY OF POLYMERS. | COMMW SCIENT IND RES ORG (AU) | 1989-09-27 | — | — | EP | disclosed |
| WO-1988004304-A1 | CONTROL OF MOLECULAR WEIGHT AND END GROUP FUNCTIONALITY OF POLYMERS | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH OR (AU) | 1988-06-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240050428-A1 | COMPOUNDS AND METHODS OF TREATING CANCERS | GSPT1, GGT1, VHL | PPARG 546/4885PPARA 2177/4885USP14 1647/4885 |
| US-20250325678-A1 | CYCLIC-AMP RESPONSE ELEMENT BINDING PROTEIN (CBP) AND/OR ADENOVIRAL E1A BINDING PROTEIN OF 300 KDA (P300) DEGRADATION COMPOUNDS AND METHODS OF USE | CREBBP, EP300, CREB1 | PPARG 717/4885PPARA 1517/4885USP14 1169/4885 |
| US-20240066133-A1 | THERAPEUTIC AGENTS AND CONJUGATES THEREOF | TLR9, STING1, TLR3 | PPARG 3046/4885PPARA 3287/4885USP14 4362/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.